1.1800
-0.0200
(-1.67%)
As of 1:01:07 PM GMT+2. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Pier Vincenzo Piazza M.D., Ph.D. | CEO & Director | 473.61k | -- | 1961 |
| Ms. Marie Line Lefevre | Head of Finance | -- | -- | -- |
| Stephanie Monlezun | Chief Operating Officer | -- | -- | -- |
| Ms. Lea Floquet | Head of Legal | -- | -- | -- |
| Mr. Arsene Guekam | Chief Corporate Development Officer | -- | -- | -- |
| Ms. Sandy Fabre | Head of Discovery & IP Leader | -- | -- | -- |
| Ms. Aurelie Boucard | Head of Preclinical Development | -- | -- | -- |
| Ms. Helle Mengel | Head of Clinical Development | -- | -- | -- |
| Ms. Corinne Chaimbault | Head of Pharmaceutical Development | -- | -- | -- |
Aelis Farma SA
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
Corporate Governance
Aelis Farma SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available